A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study

Maintenance Therapy ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial

Arobase: A phase III trial of exemestane (Exe) and bevacizumab (BEV) as maintenance therapy in patients (pts) with metastatic breast cancer (MBC) treated in first line with paclitaxel (P) and BEV—A Gineco study.

10.1200/jco.2014.32.15_suppl.501 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 501-501 ◽

Cited By ~ 2

Author(s):

Olivier Tredan ◽

Philippe Follana ◽

Isabelle Moullet ◽

Claire Cropet ◽

Stéphanie Trager-Maury ◽

...

Keyword(s):

Breast Cancer ◽

Maintenance Therapy ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial

Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial

British Journal of Cancer ◽

10.1038/sj.bjc.6603096 ◽

2006 ◽

Vol 94 (9) ◽

pp. 1233-1236 ◽

Cited By ~ 21

Author(s):

C Pacilio ◽

◽

A Morabito ◽

F Nuzzo ◽

A Gravina ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Treatment ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Single Centre ◽

Phase Iii Trial ◽

Line Chemotherapy

OT2-01-02: First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2−Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase III Trial.

10.1158/0008-5472.sabcs11-ot2-01-02 ◽

2011 ◽

Author(s):

S Beslija ◽

T Brodowicz ◽

R Greil ◽

MJ Inbar ◽

Z Kahán ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

Locally Recurrent

First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group

10.1200/jco.2004.22.14_suppl.515 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 515-515 ◽

Cited By ~ 31

Author(s):

R. Paridaens ◽

P. Therasse ◽

L. Dirix ◽

L. Beex ◽

M. Piccart ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Hormonal Treatment ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

Breast Group

Pharmacokinetics (PK) of Pertuzumab (P) With Trastuzumab (T) and Docetaxel (D) in HER2-Positive First-Line Metastatic Breast Cancer (MBC): Results From the Phase III Trial Cleopatra

Annals of Oncology ◽

10.1016/s0923-7534(20)32905-7 ◽

2012 ◽

Vol 23 ◽

pp. ix124-ix125 ◽

Cited By ~ 2

Author(s):

J. Cortes ◽

S. Swain ◽

I. Kudaba ◽

M. Hauschild ◽

T. Patel ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Her2 Positive ◽

Phase Iii Trial

Faculty Opinions recommendation of AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717998592.793477025 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Her2 Positive ◽

Phase Iii Trial ◽

First Line Therapy ◽

Line Therapy ◽

Locally Recurrent

Safety and efficacy of first-line epirubicin–docetaxel (ED) versus epirubicin–cyclophosphamide (EC): A multicenter randomized phase III trial in metastatic breast cancer (MBC)

10.1200/jco.2004.22.14_suppl.627 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 627-627 ◽

Cited By ~ 3

Author(s):

J.-U. Blohmer ◽

M. Hauschild ◽

J. Hilfrich ◽

A. Kleine-Tebbe ◽

S. Kuemmel ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

Safety And Efficacy

First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group

10.1200/jco.2004.22.90140.515 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 515-515 ◽

Cited By ~ 7

Author(s):

R. Paridaens ◽

P. Therasse ◽

L. Dirix ◽

L. Beex ◽

M. Piccart ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Hormonal Treatment ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

Breast Group

Abstract PS12-22: Maintenance therapy with everolimus plus aromatase inhibitors vs aromatase inhibitors as after first-line chemotherapy in HR+/HER2- metastatic breast cancer: Updated analyses of the phase III randomized MAIN-A trial

10.1158/1538-7445.sabcs20-ps12-22 ◽

2021 ◽

Author(s):

Valentina Guarneri ◽

Saverio Cinieri ◽

Maria Vittoria Dieci ◽

Carmelo Bengala ◽

Gabriella Mariani ◽

...

Keyword(s):

Breast Cancer ◽

Maintenance Therapy ◽

Aromatase Inhibitors ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Line Chemotherapy

Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): Subgroup analysis of the open-label non-inferiority TURANDOT phase III trial.

10.1158/1538-7445.am2013-lb-177 ◽

2013 ◽

Author(s):

Zsuzsanna Kahán ◽

Lubos Petruzelka ◽

Alexandru Eniu ◽

Rodica Anghel ◽

Krassimir Koynov ◽

...

Keyword(s):

Breast Cancer ◽

Subgroup Analysis ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Open Label ◽

Phase Iii Trial ◽

Hormone Receptor Positive